FDA’s delay on the final version of generic labelling rules until April 2017 means both branded and generic drug manufacturers face continued uncertainty.
The U.S. Food and Drug Administration (FDA) recently announced it...more
6/7/2016
/ Failure To Warn ,
Food and Drug Administration (FDA) ,
Foreseeability ,
Generic Drugs ,
Innovator Liability ,
Manufacturers ,
Pharmaceutical Industry ,
PLIVA v Mensing ,
Preemption ,
Prescription Drugs ,
Proposed Regulation ,
Warning Labels